OncoMatch/Clinical Trials/NCT05507411
Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
Is NCT05507411 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Neoadjuvant Chemotherapy and Immunotherapy for esophageal squamous cell carcinoma.
Treatment: Neoadjuvant Chemotherapy · Immunotherapy — To observe the 1-year disease-free survival rate （1-year PFS） of patients with resectable esophageal squamous cell carcinoma who received neoadjuvant chemoradiotherapy combined with camrelizumab and achieved clinical complete remission with watchful waiting strategy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Esophageal Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Disease stage
Required: Stage CT2-4ANANYM0, CT1-3N+M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chest radiotherapy
Received chest radiotherapy ... prior to the start of the trial
Cannot have received: chemotherapy
Received ... chemotherapy ... prior to the start of the trial
Cannot have received: immunotherapy
Received ... immunotherapy ... prior to the start of the trial
Cannot have received: surgery of the esophagus, esophagus and gastric junction, or stomach
Received ... surgery of the esophagus, esophagus and gastric junction, or stomach prior to the start of the trial
Lab requirements
Blood counts
WBC ≥ 2000/μL; Neutrophils ≥ 1500/μL; Platelets ≥ 100x10^3/μL; Hemoglobin ≥ 9.0 g/dL
Kidney function
Serum creatinine ≤1.5 x ULN or calculated creatinine clearance (CrCl) ≥ 50 mL/min (using Cockcroft-Gault formula)
Liver function
AST ≤ 3.0 x ULN; ALT ≤ 3.0 x ULN; Total bilirubin ≤ 1.5 x ULN (except for Gilbert syndrome participants, who had total bilirubin < 3.0 x ULN)
Laboratory screening values must meet the following criteria (using CTCAE 4th edition): i) WBC < 2000/μL; ii) Neutrophils < 1500/μL; iii) Platelets < 100x103/μL; iv) Hemoglobin < 9.0 g/dL; v) Serum creatinine <1.5 x ULN or calculated creatinine clearance (CrCl) < 50 mL/min (using Cockcroft-Gault formula); vi) AST >3.0 x ULN; vii) ALT > 3.0 x ULN; viii) Total bilirubin >1.5 x ULN (except for Gilbert syndrome participants, who had total bilirubin < 3.0 x ULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05507411 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
What disease stage is eligible?
Stage CT2-4ANANYM0 or CT1-3N+M0 is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages